PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Kadri Altundag - Top 30 Publications

Questions about lower inner zone tumors in early-stage breast cancer.

Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

Predictive role of loco-regional radiotherapy among metastatic breast cancer patients who had undergone primary tumor surgery.

Effects of tamoxifen on urinary incontinence: Case report and review of literature.

Tamoxifen has been used in women with hormone receptor-positive breast cancer and has been shown to successfully reduce both recurrence and mortality. On the contrary, long-term use of tamoxifen has hormone-related urogenital side effects which decrease the quality of life of the patients.

Do We Consider Locoregional Treatment of Primary Site in Patients With De Novo Stage IV Breast Cancer?: Numerous Data Are Accumulating!

Histopathological definition of medullary breast cancer should be revisited.

Predictive markers for trastuzumab-associated cardiac dysfunction in patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab.

Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers.

The clinical significance of synchronous bilateral breast cancer (SBBC) is unclear and its influence on prognosis is controversial. Our study objective was to determine the epidemiological features, tumor characteristics, and prognosis of SBBC in comparison with those of unilateral breast cancer (UBC).

Prognostic role of inflammatory biomarkers in metastatic breast cancer.

The effects of inflammation on the prognosis, life expectancy and several parameters such as response to treatment of breast cancer have been previously studied. The purpose of this study was to investigate the effect of inflammatory markers on prognosis in patients with metastatic breast cancer.

Association between Computer-aided Diagnosis-measured Peak Enhancement and Washout Component at Preoperative MR Imaging and Operable Hormone Receptor-positive Breast Cancer.

Immune evasion might affect survival in laryngeal cancer patients with blood group O.

Chemotherapy during Pregnancy: Cases of Hodgkin's and Non-Hodgkin's Lymphoma, Chronic Myeloid Leukemia, Breast Cancer, Nasopharyngeal Cancer, and Choriocarcinoma.

The use of chemotherapeutics during pregnancy is a dilemma for both the patient and the clinician. We report here our 11 years' experience with the use of chemotherapy during pregnancy.

Antihypertensive medication use and breast cancer risk.

Clinical and pathological factors related to brain relapse-free survival in breast cancer patients.

HER2 status might be independent determinant associated with no residual disease at surgical resection in patients with DCIS.

Safety Analysis of Premenopausal Breast Cancer Patients in PALOMA-3 Study: Is It Worth Mentioning?

Some pathological and clinical factors are important to describe association between Ki67 expression and recurrences in breast cancer patients receiving neoadjuvant chemotherapy.

Breast Cancer Molecular Subtypes and Chemotherapy Schedules Used in Neoadjuvant or Adjuvant Setting May Show Different Effects in Nipple-Sparing Mastectomy.

Playing brass instruments by breast cancer patients: A way of combating anxiety.

Biopsy from Recurrent Lesion May Change Further Treatment Plan in Metastatic Breast Cancer.

Why do younger breast cancer patients with blood group O have favorable prognosis?

Coadministration of proton pump inhibitors may decrease the efficacy of capecitabine in metastatic breast cancer patients.

Regular daily consumption of turmeric may be a complementary agent for the adjuvant treatment of hormone receptor positive breast cancer.

Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.

It is well-known that tumor phenotype may change during the progression of breast cancer (BC). The purpose in this study was to compare the discordance in estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) between primary and recurrent/metastatic lesions (RML) and also to evaluate the prognostic significance of change in tumor phenotype on survival in patients with metastatic BC.

The short-term safety of adjuvant paclitaxel plus trastuzumab - A single centre experience.

HER2-amplified breast cancer (BC) has a poor prognosis. The combination of trastuzumab with chemotherapy in the adjuvant setting decreases recurrence and improves overall survival in HER2-positive BC. However, the role of adjuvant treatment in patients with HER2-amplified small BC without lymph node involvement is still under debate. The purpose of this study was to investigate the safety of adjuvant paclitaxel and trastuzumab (APT) in this group of patients.

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers.

Letter to the Editor. Characteristics influencing preoperative neutrophil-to-lymphocyte ratio.

HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?

Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.

Invasive pleomorphic lobular carcinoma (IPLC) is defined to be an uncommon and different subtype of classical invasive lobular carcinoma (ILC). This special variant is characterized by significant cytological atypia and pleomorphism which differs from the cytological uniformity of ILC. IPLC has been shown to have some poor prognostic factors such as axillary node metastasis and higher histological grade which may lead to poor clinical courses including a short relapse time, increased risk of recurrence and a decreased survival. The aim of this study is to investigate the clinicopathological characteristics and prognosis of IPLC in comparison with ILC and also to evaluate if IPLC is a different clinical entity compared to ILC. A total number of 4418 breast cancer patients treated between 1996 and 2015 in Hacettepe University Cancer Institute, were retrospectively analyzed. Among 4418 patients, 210 were diagnosed with ILC and 23 patients diagnosed with pure IPLC. In this present study, clinicopathological characteristics, disease free survival (DFS) and overall survival (OS) of patients with ILC and IPLC were compared. This study design is one of the rare face to face comparison of pure IPLC and ILC. Patients with IPLC had an increased rate of higher histologic grade, extracapsular extension, lymphovascular invasion and lower percentage of hormone positivity than those of patients with ILC. During the follow-up time, IPLC group experienced 4 cases (17.3%) of recurrence, 5 cases (21.7%) of death and 2 cases (8.7%) of progression in 3 metastatic patients compared to that of 27 cases (12.9%) of recurrence, 29 cases (13,8%) of death and 14 cases (6.7%) of progression in 19 metastatic patients in the ILC group. Patients with IPLC had a worse DFS and OS duration than patients with ILC (P = 0.02 for OS, P = 0.04 for DFS). In conclusion, IPLC is a different and a special breast cancer subtype. This study suggests that IPLC is a distinct clinical entity with an advanced stage and more aggressive clinical course. Patients with IPLC reveal poorer prognostic factors such as higher histological grade, relative lower percentages of hormone positivity, and increased rate of recurrences resulting in poor clinical outcomes and worse survival. Nowadays, it is observed that current treatment methods for IPLC do not seem as successful as in ILC and failed to be effective. Thence, individual therapies including more aggressive surgery and adjuvant or neoadjuvant chemotherapy even in the earlier stages of breast cancer should be performed for this distinct variant.

Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw: Expected for Multiple Myeloma, But Unusual for Breast Cancer.